Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Treatment Study for Patients with Ovarian Cancer
This is a phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
In order to participate you must meet the following criteria:
- Have newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Have completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking).
- Have completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator.
- Have sufficient tumor tissue for planned analysis.
You will be excluded from the study if any of the following criteria apply to you:
- Have pure sarcomas or borderline tumors or mucinous tumors.
- Have active second malignancy.
- Have known central nervous system brain metastases.
- Have any prior treatment for ovarian cancer, other than the first-line platinum regimen.
This is a partial list of inclusion and exclusion criteria.